Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered that while the genes provided by the father arrive at fertilization pre-programmed to the state needed by the embryo, the genes provided by the mother are in a different state and must be reprogrammed to match. The findings have important implications for both developmental biology and cancer biology.
Office of Public Affairs
2000 Circle of Hope,
Salt Lake City, UT 84112
Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have developed a novel and powerful technique to identify the targets for a group of enzymes called RNA cytosine methyltransferases (RMTs) in human RNA. They applied their technique to a particular RMT, NSUN2, which has been implicated in mental retardation and cancers in humans, finding and validating many previously unknown RMT targets—an indication of the technique's power. The research results were published online in the journal Nature Biotechnology on April 21.
John Sweetenham, M.D., currently a Professor of Medicine at the University of California, San Diego, and Medical Director of the UCSD University of Nevada Cancer Institute, has been appointed Senior Director of Clinical Affairs and Executive Medical Director at Huntsman Cancer Institute (HCI), and Professor in the Department of Medicine, Division of Hematologic Oncology at the University of Utah after a national search. He will assume his post April 1.
People who reside in rural areas of Utah are less likely to follow colorectal cancer (CRC) screening recommendations than their urban counterparts, according to researchers from Huntsman Cancer Institute (HCI) at the University of Utah. This geographic disparity is evident across all risk groups, including those who have a family history of the disease.
HCI researchers were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic lymphoma (Ph+ ALL).
Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today’s online issue of the journal Oncogene.
A new discovery from researchers at HCI concerning a fundamental understanding about how DNA works will produce a "180-degree change in focus" for researchers who study how gene packaging regulates gene activity, including genes that cause cancer and other diseases.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance." This can be a problem, as people with Lynch syndrome have a much higher probability to develop colon cancer, and often develop colon cancer at an earlier age than is common among the general population; consequently, they need to begin screening at a much younger age.
Cancer affects everyone. Half of all men and one-third of all women will get cancer in their lifetimes. Exercise, eating healthfully, and getting recommended cancer screenings all contribute to avoiding cancer; the right coping strategies, good nutrition, and accessible support services can make the journey easier for those who have already been diagnosed.
For the first time, a mutation in HIF2α, a specific group of genes known as transcription factors that is involved in red blood cell production and cell metabolism, has been identified in cancer tumor cells.
A new mobile web service has been developed to help patients, family members, community physicians, or anyone, find out the most current information about HCI's clinical trials.
A new study of the genetic makeup, or genome, of Ewing sarcoma, a rare cancer that strikes children, teenagers, and young adults, has produced multiple discoveries: a previously unknown sarcoma subtype, genetic factors related to long-term survival, and identification of a genetic change between the primary and metastatic stages of the disease that could lead to better, more targeted treatment.
Cells in normal tissue seem to have "personal space" issues. They know how much space they like, and if things get too tight, some cells are forced to leave.
A new compound shows promise in patient leukemia samples when current treatments fail, say researchers from Huntsman Cancer Institute (HCI) at the University of Utah (U of U).
Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study published online today in the American Journal of Human Genetics.
Researchers from HCI report they have discovered a method to identify cancer-causing rearrangements of genetic material called chromosomal translocations quickly, accurately, and inexpensively.
It's never too early to learn about sun safety, say a group of concerned Utah physicians. That's why they've partnered with the SHADE Foundation and the US Environmental Protection Agency (EPA) to bring a national poster contest to Utah students from kindergarten to eighth grade.
Huntsman Cancer Institute (HCI) at the University of Utah is now offering lung-cancer screening using low-radiation CT (computed tomography) technology.
Huntsman Cancer Institute at the University of Utah (HCI) today announced that Jon M. Huntsman, Jr. will be appointed to the position of Chairman of the Huntsman Cancer Foundation (the Foundation), effective immediately.
Precise, accurate imaging—think mammography, CT and MRI scans—is important to cancer screening, treatment, and follow-up care. Now, even more advanced technology is emerging, and with it, the need for imaging specialists with the expertise to use them.
Our media relations representatives are here to help reporters Monday-Friday, 7:30 am-5 pm.
Public Affairs Manager
Public Relations Associate
After-hours calls: Reporters calling before or after business hours on an urgent matter can page the University of Utah Health on-call media relations representative at 801-581-7387 and press 1.